Mixed results for AstraZeneca in Scotland while patient access scheme swings yes for Pfizer
This article was originally published in Scrip
There was mixed news for AstraZeneca in Scotland after the country's health technology appraisal body, the Scottish Medicines Consortium, turned down Seroquel (quetiapine) for major depressive episodes in bipolar disorder but accepted Brillique (ticagrelor)for atherothrombotic events in adult with acute coronary syndromes. Meanwhile, a patient access scheme helped Pfizer secure a yes for its Sutent (sunitinib).
You may also be interested in...
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.